CH603545A5 - - Google Patents

Info

Publication number
CH603545A5
CH603545A5 CH568673A CH568673A CH603545A5 CH 603545 A5 CH603545 A5 CH 603545A5 CH 568673 A CH568673 A CH 568673A CH 568673 A CH568673 A CH 568673A CH 603545 A5 CH603545 A5 CH 603545A5
Authority
CH
Switzerland
Application number
CH568673A
Inventor
Arthur Dr Rer Nat Scherm
Dezsoe Dr Peteri
Original Assignee
Merz & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2219256A external-priority patent/DE2219256C3/de
Priority claimed from DE2318461A external-priority patent/DE2318461A1/de
Application filed by Merz & Co filed Critical Merz & Co
Publication of CH603545A5 publication Critical patent/CH603545A5/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CH568673A 1972-04-20 1973-04-19 CH603545A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2219256A DE2219256C3 (de) 1972-04-20 1972-04-20 Oral und parenteral verabreichbares Arzneimittel zur Behandlung der Parkinson'sehen Krankheit
DE2318461A DE2318461A1 (de) 1973-04-12 1973-04-12 Verfahren zur herstellung von 1,3,5trisubstituierten adamanta-verbindungen

Publications (1)

Publication Number Publication Date
CH603545A5 true CH603545A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1978-08-31

Family

ID=25763107

Family Applications (1)

Application Number Title Priority Date Filing Date
CH568673A CH603545A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1972-04-20 1973-04-19

Country Status (8)

Country Link
US (1) US4122193A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS4918860A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA974518A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH603545A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES413944A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2182998B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1393503A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL7305644A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
WO1992017168A1 (en) * 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
CA2457011C (en) * 2001-08-20 2012-04-24 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
EP1298581A1 (fr) * 2001-09-27 2003-04-02 C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
AU2003274353B2 (en) 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
RU2246482C2 (ru) * 2002-12-25 2005-02-20 ООО "Циклан" Способ получения гидрохлорида 1-амино-3,5-диметиладамантана
CA2528622C (en) * 2003-05-27 2010-08-03 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
CN1240668C (zh) * 2003-09-10 2006-02-08 上海医药工业研究院 一种新的盐酸美金刚制备方法
CA2540921A1 (en) * 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic ass peptides in amyloidopathies
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
WO2005069742A2 (en) * 2003-12-10 2005-08-04 Sun Pharmaceutical Industries Limited Crystal form ii of memantine hydrochloride
CA2551689A1 (en) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer's disease
CN100363329C (zh) * 2004-01-09 2008-01-23 南京大学 合成美金刚胺盐酸盐的方法
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EA011446B1 (ru) * 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
BRPI0512263A (pt) 2004-06-17 2008-02-26 Merz Pharma Gmbh & Co Kgaa formulações de liberação imediata de formas de dosagem oral de memantina
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
CN101374525A (zh) * 2004-09-23 2009-02-25 莫茨药物股份两合公司 美金刚治疗儿童行为障碍
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EP1836157B1 (en) * 2005-01-11 2009-10-07 Teva Pharmaceutical Fine Chemicals S.R.L. Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
ITMI20050833A1 (it) 2005-05-10 2006-11-11 A M S A S P A Anonima Materie Sintetiche Affini Nuovo procedimento per la sintesi di aminoadamantani
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
EP1915146A4 (en) 2005-07-27 2010-06-02 Dov Pharmaceutical Inc NOVEL 1-ARYL-3-AZABICYCLO [3.1.0] HEXANEES. PREPARATION AND USE FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
PT1820792E (pt) * 2006-02-21 2012-04-10 Hexal Ag Processo para a preparação de adamantanaminas
BRPI0702852A2 (pt) * 2006-03-27 2012-08-07 Teva Pharmaceutical Ind Ltda processos para preparaÇço de Ácido hidroclorÍdrico de memantine substancialmente livre de impurezas, para determinar o grau de pureza do mesmo e para fabricaÇço de produto famacÊutico derivado; seus compostos e componentes
CA2659876A1 (en) 2006-08-04 2008-02-07 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP1908748A1 (en) * 2006-10-05 2008-04-09 Krka Process for the preparation of memantine and its hydrochloric acid salt form
WO2008063847A2 (en) * 2006-11-03 2008-05-29 Forest Laboratories Holdings Limited Method for treating autism
AU2007333656A1 (en) 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
CA2679263A1 (en) 2007-02-28 2008-09-04 Asahi Kasei Pharma Corporation Sulfonamide compound
US20090069374A1 (en) 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0713930D0 (en) 2007-07-18 2007-08-29 Generics Uk Ltd Novel assay methods
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2111858A1 (en) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Novel treatment for alzheimer's disease
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
JP5195256B2 (ja) * 2008-10-10 2013-05-08 東ソー株式会社 アミノアダマンタン誘導体の製造方法
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
WO2010112221A1 (en) 2009-04-03 2010-10-07 Synthon B.V. Pharmaceutical compositions comprising memantine
CN102070463A (zh) * 2009-06-11 2011-05-25 辽宁利锋科技开发有限公司 具有金刚烷结构药物美金刚胺及其衍生物和类似物抗肿瘤新适应症的应用
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
WO2012052451A1 (en) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
AU2011322565A1 (en) 2010-10-29 2013-05-30 Merz Pharma Gmbh & Co. Kgaa Indole derivatives and process for their preparation
AU2011328993B2 (en) 2010-11-15 2017-03-02 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012085166A1 (en) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2012085167A1 (en) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
WO2012152854A1 (en) 2011-05-12 2012-11-15 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN103288650B (zh) * 2012-02-28 2015-09-30 广州白云山制药股份有限公司广州白云山制药总厂 一种盐酸1-氨基-3,5-二甲基金刚烷的制备方法
EP2650284A1 (en) 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Heterocyclic derivatives as metabotropic glutamate receptor modulators
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
US10329301B2 (en) 2013-12-20 2019-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX383665B (es) 2014-02-04 2025-03-14 Forest Laboratories Holdings Ltd Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
EP3310785B1 (en) 2015-06-19 2024-11-20 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6354701B2 (ja) * 2015-08-19 2018-07-11 大日本印刷株式会社 高純度メマンチン塩酸塩の製造法
KR102774558B1 (ko) 2015-12-30 2025-03-04 코리움, 엘엘씨 장기 경피 투여를 위한 시스템 및 방법
US11541018B2 (en) 2016-06-23 2023-01-03 Corium, Llc Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
CN109789134A (zh) 2016-07-27 2019-05-21 考里安国际公司 与口服递送药代动力学生物等效的透皮递送系统
KR102545643B1 (ko) 2016-07-27 2023-06-21 코리움, 엘엘씨 도네페질 경피 전달 시스템
MX2019001104A (es) 2016-07-27 2019-10-02 Corium Int Inc Sistemas de suministro transdermico de memantina.
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
JP2019094304A (ja) * 2017-11-27 2019-06-20 学校法人順天堂 オートファジー誘導剤
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
BR112020026062B1 (pt) 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
EP3721857A1 (en) * 2019-04-11 2020-10-14 Dentsply DeTrey GmbH Dental composition
US11639328B2 (en) 2020-05-19 2023-05-02 Shandong Holly Pharmaceutical Co., Ltd. Method for preparing amantadine
IL319072A (en) 2022-08-19 2025-04-01 Agenebio Inc History of Benzazepine, Compositions and Methods for Treating Cognitive Impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH76A (fr) * 1888-11-14 1889-01-09 Carnal Paul E Nouveau système de boîte de montre pouvant servir à volonté comme savonnette ou comme boîte à glace
US3391142A (en) * 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
FR1545327A (fr) * 1966-11-25 1968-11-08 Boehringer Sohn Ingelheim Nouveau procédé de fabrication de 2-hydroxy-3-aryloxy-propylamines secondaires
US3450761A (en) * 1967-03-30 1969-06-17 Sun Oil Co 1-aminoethyldimethyladamantane
US3929888A (en) * 1968-08-27 1975-12-30 Lilly Industries Ltd 2-Phenyl-adamantanealkylamine compounds and their salts
US3789073A (en) * 1970-04-22 1974-01-29 Squibb & Sons Inc Adamantylalkylaminoalkyl benzamides

Also Published As

Publication number Publication date
ES413944A1 (es) 1976-06-01
GB1393503A (en) 1975-05-07
FR2182998B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1976-12-31
FR2182998A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1973-12-14
US4122193A (en) 1978-10-24
NL7305644A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1973-10-23
JPS4918860A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1974-02-19
CA974518A (en) 1975-09-16

Similar Documents

Publication Publication Date Title
AR202780Q (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH568662A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH586535B5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH558448A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH559034A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH559601A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH559862A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH559941A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH560078A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH561417A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH561483A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH561875A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH561888A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH561897A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH561966A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH562070A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH581087A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH563593A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH565410A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH565493A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH566525A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH567324A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH568483A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH581615A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH586201A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Legal Events

Date Code Title Description
PL Patent ceased
PL Patent ceased